Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2011-09-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2011.06.099PMID 21831638PMCID PMC3292863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-cancer drugs

  2012cited by this paper
• Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic Cancer

  2010cited by this paper
• Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

  2010cited by this paper
• Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion.

  2010cited by this paper
• Lipophilic 2,5-disubstituted pyrroles from the marine sponge Mycale sp. inhibit mitochondrial respiration and HIF-1 activation.

  2009cited by this paper
• Identification of a Novel Small Molecule HIF-1α Translation Inhibitor

  2009cited by this paper
• Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment.

  2008cited by this paper
• Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.

  2007cited by this paper
• Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.

  2006cited by this paper
• Inhibitors of hypoxia-inducible factor-1 signaling.

  2006cited by this paper
• Proteasomal Inhibition Attenuates Transcriptional Activity of Hypoxia-Inducible Factor 1 (HIF-1) via Specific Effect on the HIF-1α C-Terminal Activation Domain

  2006cited by this paper
• Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.

  2005cited by this paper
• Hypoxia inducible factor-1: a novel target for cancer therapy

  2005cited by this paper
• Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

  2005cited by this paper
• Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors

  2004cited by this paper
• Tumor-specific gene expression using the survivin promoter is further increased by hypoxia

  2004cited by this paper
• A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy

  2003cited by this paper
• Replicative Oncolytic Adenoviruses in Multimodal Cancer Regimens

  2003cited by this paper
• FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor.

  2002cited by this paper
• Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation

  2002cited by this paper
• Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells

  2001cited by this paper
• Natural Product-like Combinatorial Libraries Based on Privileged Structures. 2. Construction of a 10 000-Membered Benzopyran Library by Directed Split-and-Pool Chemistry Using NanoKans and Optical Encoding

  2000cited by this paper
• Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines.

  1999cited by this paper
• Necrogenesis and Fas/APO-1 (CD95) Expression in Primary (de novo) and Secondary Glioblastomas

  1998cited by this paper
• Nonlinear mixed effects models for repeated measures data.

  1990cited by this paper

• A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: Design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments.

  2024cites this paper
• Molecular docking and pharmacophore models to probe binding hypothesis of inhibitors of hypoxia inducible factor-1

  2021cites this paper
• Structure Activity Relationship of Key Heterocyclic Anti-Angiogenic Leads of Promising Potential in the Fight against Cancer

  2021cites this paper
• Conditional Antisense Oligonucleotides Triggered by miRNA.

  2021cites this paper
• Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth

  2021cites this paper
• Structural and biological study of synthesized anthraquinone series of compounds with sulfonamide feature

  2019cites this paper
• Hypoxia‐inducible factor‐1 (HIF‐1) inhibitors from the last decade (2007 to 2016): A “structure–activity relationship” perspective

  2018cites this paper
• Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma

  2018cites this paper
• Novel Hypoxia-Inducible Factor 1α (HIF-1α) Inhibitors for Angiogenesis-Related Ocular Diseases: Discovery of a Novel Scaffold via Ring-Truncation Strategy.

  2018cites this paper
• Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility

  2017cites this paper
• Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway.

  2017cites this paper
• A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis

  2017cites this paper
• Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example.

  2017cites this paper
• Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease.

  2017cites this paper
• Hypoxia inducible factor (HIF) as a model for studying inhibition of protein–protein interactions

  2017cites this paper
• Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories.

  2017cites this paper
• Synthesis, Development, and Exploration of Two Small Molecule Scaffolds Toward Discovery of Novel and Potent Inhibitors of the Hypoxia-Inducible Factor-1 Pathway

  2017cites this paper
• Synthesis, crystallographic characterization, DFT and TD-DFT studies of Oxyma-sulfonate esters

  2017cites this paper
• Design and Synthesis of Inhibitors of Hypoxia Inducible Factor-1-mediated Functions

  2017cites this paper
• A Review on Some Proposed Targets and its Effective Molecules in Cancer Disease

  2016cites this paper
• Targeting Protein–Protein Interactions in the HIF System

  2016cites this paper
• Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway.

  2016cites this paper
• Enantioselective Suzuki cross-couplings of unactivated 1-fluoro-1-haloalkanes: synthesis of chiral β-, γ-, δ-, and ε-fluoroalkanes.

  2015cites this paper
• Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives

  2015cites this paper
• Design and Synthesis of Small-molecule Inhibitors of the Hypoxia Inducible Factor-1 as Anticancer Therapeutics

  2014cites this paper
• Biology of advanced uveal melanoma and next steps for clinical therapeutics

  2014cites this paper
• Small-Molecule Proteomimetic Inhibitors of the HIF-1α–p300 Protein–Protein Interaction

  2014cites this paper
• Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

  2013cites this paper
• Design and Synthesis of HIF-1 Inhibitors as Anti-cancer Therapeutics

  2013cites this paper
• Design and in vitro activities of N -alkyl- N -[(8- R -2,2-dimethyl- 2H -chromen-6-yl)methyl]heteroarylsulfonamides, novel small molecule Hypoxia Inducible Factor-1 (HIF-1) pathway inhibitors and anti-cancer agents

  2013cites this paper
• Sulfonamide Synthesis via Oxyma-O-sulfonates – Compatibility to Acid Sensitive Groups and Solid-Phase Peptide Synthesis

  2013cites this paper
• Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP

  2012cites this paper
• KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology

  2012cites this paper
• Cancer Therapy : Preclinical Arylsulfonamide KCN 1 Inhibits In Vivo Glioma Growth and Interfereswith HIF Signaling byDisrupting HIF-1 a Interaction with Cofactors p 300 / CBP

  2012cites this paper
• Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.

  2012cites this paper
• Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.

  2012cites this paper
• Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent.

  2012cites this paper
• Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.

  2011cites this paper
• Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1? interaction with co-factors p300/CBP

  year unknowncites this paper